CK0803 Treg Therapy Seems Safe for ALS, Trial Set to Treat Second Cohort
The positive DSMB recommendation came after no participants were found to experience any serious adverse events from the therapy.
Cellenkos is moving forward with treating the second cohort of patients with
"We are very excited and encouraged by this development," Tara Sadeghi, Chief Operating Officer, Cellenkos, said in a statement.1 "This recommendation from the DSMB is an important step in bringing this potential disease modifying therapy to the patients and takes us closer to our ultimate goal of curing ALS."
The positive DSMB recommendation came after no participants were found to experience any serious adverse events from the therapy. The REGALS trial will continue to enroll in its safety run-in study before proceeding to a phase 1b, randomized, double blind, placebo control trial of CK0803 that will access 4 weekly infusions followed by 5 monthly infusions in participants with ALS.
CK0803 is a novel, allogeneic, neurotrophic, clinical-grade umbilical cord blood-derived cell therapy that consists of Treg cells with a high cell surface expression of CD11a, that leverage CXCR3/CXCL10 axis to engage with the inflamed microglia. It is developed using Cellenkos' proprietary CRANE® technology, to generate disease-specific products. Cell products do not need to be HLA or ABO-matched to the recipient and multiple doses of CK0803 can be manufactured from a single umbilical cord blood unit and cryopreserved until ready for use.
WATCH NOW:
"We are excited to participate in this important study of this novel allogeneic Treg cell product in patients with ALS," principal investigator Neil Shneider, MD, PhD, associate professor, neurology and director, Eleanor and Lou Gehrig ALS Center, Columbia, said in an earlier statement.2 "Promising data from six ALS patients previously treated with allogeneic cord blood Treg cells through an expanded access program at our Center supports the clinical development of CK0803, and we are grateful to Cellenkos for their commitment to applying their technology to ALS".
REGALS stands for Regulatory T Cells for Amyotrophic Lateral Sclerosis and is a multicenter study being conducted across Columbia University, New York; Michael E. DeBakey VA Medical Center, Houston and Baylor College of Medicine, Houston. The study is primarily aiming to establish safety and tolerability of multiple doses of CK0803 in patients with ALS. The study will also assess the primary endpoint of combined assessment of function and survival (CAFS) based on survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score, and a secondary endpoint of longitudinal measurement of neurofilament light chain levels in serum and cerebrospinal fluid (CSF) in order to evaluate preliminary efficacy.
"The dosing of the first patient marks an exciting milestone for our company. The initiation of this study of CK0803 is an important achievement that brings us closer to delivering a potential new treatment which may have a life-changing impact for ALS," Sadeghi said when the
REFERENCES
1. Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial. News release. February 19, 2024. https://www.prnewswire.com/news-releases/cellenkos-approved-to-proceed-with-ck0803-neurotrophic-t-regulatory-cell-therapy-to-treat-second-cohort-in-als-trial-302064780.html
2. Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis. News release. Cellenkos. May 2, 2023. https://www.prnewswire.com/news-releases/cellenkos-announces-first-patient-dosed-with-ck0803-cell-therapy-for-treatment-of-amyotrophic-lateral-sclerosis-301812682.html
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025